Clear Street’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-2,637
Closed -$107 1580
2023
Q1
$107 Buy
+2,637
New +$182 ﹤0.01% 1102

Clear Street's EUCRW Position: Q2 2023 in Review

Clear Street sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 2,637 shares — an estimated $107 sold.

Clear Street first reported a position in EUCRW in Q1 2023 and held it in 1 quarter. The position peaked at $107 in Q1 2023. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

  • Clear Street reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
  • Clear Street sold 2,637 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $107.
  • Clear Street first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2023 and held it in 1 quarter.
  • Clear Street's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $107 in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Clear Street's 13F filing for Q2 2023, filed 14 Aug 2023.